Weighted Average Number of Shares Outstanding, Basic of ARROWHEAD PHARMACEUTICALS, INC. from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
ARROWHEAD PHARMACEUTICALS, INC. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • ARROWHEAD PHARMACEUTICALS, INC. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 137,039,000, a 9.8% increase year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 133,758,000, a 12% increase from 2024.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 119,784,000, a 12% increase from 2023.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 106,750,000, a 1.3% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

ARROWHEAD PHARMACEUTICALS, INC. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 137,039,000 +12,191,000 +9.8% 01 Oct 2025 31 Dec 2025 10-Q 05 Feb 2026 2026 Q1
Q3 2025 133,758,000 +13,974,000 +12% 01 Jul 2025 30 Sep 2025 10-K 25 Nov 2025 2025 FY
Q2 2025 139,039,000 +14,840,000 +12% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q3
Q1 2025 133,363,000 +10,078,000 +8.2% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q2
Q4 2024 124,848,000 +17,433,000 +16% 01 Oct 2024 31 Dec 2024 10-Q 05 Feb 2026 2026 Q1
Q3 2024 119,784,000 +13,034,000 +12% 01 Jul 2024 30 Sep 2024 10-K 25 Nov 2025 2025 FY
Q2 2024 124,199,000 +17,195,000 +16% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q3
Q1 2024 123,285,000 +16,528,000 +15% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q2
Q4 2023 107,415,000 +1,376,000 +1.3% 01 Oct 2023 31 Dec 2023 10-Q 10 Feb 2025 2025 Q1
Q3 2023 106,750,000 +1,324,000 +1.3% 01 Jul 2023 30 Sep 2023 10-K 25 Nov 2025 2025 FY
Q2 2023 107,004,000 +1,251,000 +1.2% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q3
Q1 2023 106,757,000 +1,212,000 +1.1% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q2
Q4 2022 106,039,000 +1,505,000 +1.4% 01 Oct 2022 31 Dec 2022 10-Q 06 Feb 2024 2024 Q1
Q3 2022 105,426,000 +1,681,000 +1.6% 01 Jul 2022 30 Sep 2022 10-K 26 Nov 2024 2024 FY
Q2 2022 105,753,000 +1,654,000 +1.6% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q3
Q1 2022 105,545,000 +1,678,000 +1.6% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q2
Q4 2021 104,534,000 +1,777,000 +1.7% 01 Oct 2021 31 Dec 2021 10-Q 06 Feb 2023 2023 Q1
Q3 2021 103,745,000 +3,023,000 +3% 01 Jul 2021 30 Sep 2021 10-K 29 Nov 2023 2023 FY
Q2 2021 104,099,000 +2,256,000 +2.2% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q3
Q1 2021 103,867,000 +2,214,000 +2.2% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q2
Q4 2020 102,757,000 +5,667,000 +5.8% 01 Oct 2020 31 Dec 2020 10-Q 02 Feb 2022 2022 Q1
Q3 2020 100,722,000 +6,863,000 +7.3% 01 Jul 2020 30 Sep 2020 10-K 28 Nov 2022 2022 FY
Q2 2020 101,843,000 +6,907,529 +7.3% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q3
Q1 2020 101,653,000 +7,497,593 +8% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q2
Q4 2019 97,090,000 +5,998,177 +6.6% 01 Oct 2019 31 Dec 2019 10-Q 04 Feb 2021 2021 Q1
Q3 2019 93,859,000 +10,220,531 +12% 01 Jul 2019 30 Sep 2019 10-K 22 Nov 2021 2021 FY
Q2 2019 94,935,471 +7,301,036 +8.3% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q3
Q1 2019 94,155,407 +10,071,470 +12% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q2
Q4 2018 91,091,823 +16,260,408 +22% 01 Oct 2018 31 Dec 2018 10-Q 05 Feb 2020 2020 Q1
Q3 2018 83,638,469 01 Jul 2018 30 Sep 2018 10-K 23 Nov 2020 2020 FY
Q2 2018 87,634,435 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019 2019 Q3
Q1 2018 84,083,937 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q2
Q4 2017 74,831,415 01 Oct 2017 31 Dec 2017 10-Q 07 Feb 2019 2019 Q1
Q2 2012 11,238,291 +4,055,663 +56% 01 Apr 2012 30 Jun 2012 10-Q 13 Aug 2012 2012 Q3
Q1 2012 10,663,869 +3,483,200 +49% 01 Jan 2012 31 Mar 2012 10-Q 08 May 2012 2012 Q2
Q2 2011 7,182,628 -57,396,775 -89% 01 Apr 2011 30 Jun 2011 10-Q 13 Aug 2012 2012 Q3
Q1 2011 7,180,669 01 Jan 2011 31 Mar 2011 10-Q 08 May 2012 2012 Q2
Q2 2010 64,579,403 01 Apr 2010 30 Jun 2010 10-Q 08 Aug 2011 2011 Q3

ARROWHEAD PHARMACEUTICALS, INC. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 133,758,000 +13,974,000 +12% 01 Oct 2024 30 Sep 2025 10-K 25 Nov 2025 2025 FY
2024 119,784,000 +13,034,000 +12% 01 Oct 2023 30 Sep 2024 10-K 25 Nov 2025 2025 FY
2023 106,750,000 +1,324,000 +1.3% 01 Oct 2022 30 Sep 2023 10-K 25 Nov 2025 2025 FY
2022 105,426,000 +1,681,000 +1.6% 01 Oct 2021 30 Sep 2022 10-K 26 Nov 2024 2024 FY
2021 103,745,000 +3,023,000 +3% 01 Oct 2020 30 Sep 2021 10-K 29 Nov 2023 2023 FY
2020 100,722,000 +6,863,000 +7.3% 01 Oct 2019 30 Sep 2020 10-K 28 Nov 2022 2022 FY
2019 93,859,000 +10,220,531 +12% 01 Oct 2018 30 Sep 2019 10-K 22 Nov 2021 2021 FY
2018 83,638,469 +9,739,871 +13% 01 Oct 2017 30 Sep 2018 10-K 23 Nov 2020 2020 FY
2017 73,898,598 01 Oct 2016 30 Sep 2017 10-K 25 Nov 2019 2019 FY
2012 11,129,766 +3,948,645 +55% 01 Oct 2011 30 Sep 2012 10-K 28 Dec 2012 2012 FY
2011 7,181,121 +746,876 +12% 01 Oct 2010 30 Sep 2011 10-K 28 Dec 2012 2012 FY
2010 6,434,245 01 Oct 2009 30 Sep 2010 10-K 20 Dec 2011 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.